fig2
From: Cathepsin K: both a likely biomarker and a new therapeutic target in lymphangioleiomyomatosis?
Figure 2. Selective inhibition of the collagenolytic activity of cathepsin K by targeting its exosite. Schematic drawing summarizing the overall strategy to target cathepsin K by exosite-binding inhibitors.
